Gyre Therapeutics Inc.
GYRE | NASDAQ
$4.55
-$1.86 (-29.02%)
At close: Oct 30, 2026, 4:00 PM ET
$4.55
$0.00 (+0.11%)
Pre-market:
Nov 2, 2026, 8:23 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 125.40 | 86.43 | -16.87 | 265 | -4.76 | -32.30 |
PEG Ratio | -2.10 | -0.79 | 0 | -2.62 | 2.32 | 0.96 |
PS Ratio | 5.41 | 9.74 | 13.80 | 5.88 | 57 | 86.66 |
PB Ratio | 5.95 | 16.26 | -98.95 | 14.15 | 10.18 | 23.86 |
P/FCF Ratio | -3.5K | -152.11 | 90.50 | 105.95 | -4.94 | -32.82 |
P/OCF Ratio | 624.53 | -282.79 | 60.49 | 56.36 | -4.99 | -32.98 |
OCF/S Ratio | 0.87 | -3.44 | 22.82 | 10.44 | -1.14K | -262.78 |
Debt / Equity Ratio | 0.01 | 0.03 | -0.03 | 0.01 | 0.06 | 0.02 |
Quick Ratio | 5.04 | 2.99 | 2.64 | 3.56 | 3.57 | 5.03 |
Current Ratio | 5.60 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 |
Asset Turnover | 0.70 | 0.84 | 0.97 | 1.21 | 0.13 | 0.22 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | 4.74% | 19.09% | 587.14% | 5.41% | -214.01% | -73.02% |
Return on Assets | 3.03% | 9.64% | -79.74% | 2.72% | -157.98% | -58.56% |
Return on Invested Capital | 5.30% | 11.74% | -69.52% | 5.78% | -192.59% | -72.91% |
Dividend Yield | n/a | n/a | 15.13% | 269.81% | n/a | n/a |
Payout Ratio | n/a | n/a | -255.02% | 70.52K% | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 95.35% | 96.33% | 95.91% | 95.31% | -4.52% | 56.26% |
Net Profit Margin | 4.31% | 11.43% | -81.92% | 2.25% | -1.2K% | -265.14% |
Pretax Profit Margin | 12.38% | 21.95% | -67.84% | 9.20% | -1.2K% | -268.48% |
Operating Profit Margin | 9.86% | 15.35% | -59.26% | 9% | -1.14K% | -273.87% |
FCF Margin | -0.15% | -6.40% | 15.25% | 5.55% | -1.15K% | -264.06% |
EBITDA Margin | 14.54% | 16.85% | 17.92% | 10.30% | -1.19K% | -267.82% |
Add to Watchlist
Select watchlists to add or remove GYRE